All In Biotech

Drug Trial Radar · NCT02155660

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations.

Last checked: Nov 20, 2026Latest source record: Jun 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,255 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,255

Actual

Start

Jun 25, 2014

Primary completion

Apr 9, 2018

Study completion Apr 9, 2018

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
MedImmune LLC
First posted
Jun 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies.

Conditions

  • Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Interventions

  • Benralizumab Arm ADrug

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

  • Benralizumab Arm BDrug

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

  • Benralizumab Arm CDrug

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

  • PlaceboDrug

    Benralizumab subcutaneously on study week 0 until study week 48 inclusive

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uLTime frame: Immediately following the first IP dose through week 56

Locations

356 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Gulf Shores, Alabama

  • Research Site

    Montgomery, Alabama

  • Research Site

    Flagstaff, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Anaheim, California

  • Research Site

    Arcadia, California

  • Research Site

    Bakersfield, California

  • Research Site

    Fresno, California

  • Research Site

    Fullerton, California

  • Research Site

    Hawaiian Gardens, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Northridge, California

  • Research Site

    Palmdale, California

  • Research Site

    Peninsula, California

  • Research Site

    Placentia, California

  • Research Site

    Rolling Hills Estates, California

  • Research Site

    Westminster, California

  • Research Site

    Centennial, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Denver, Colorado

  • Research Site

    Chiefland, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Coconut Creek, Florida

  • Research Site

    Coral Gables, Florida

  • Research Site

    Daytona Beach, Florida

  • Research Site

    DeBary, Florida

  • Research Site

    DeLand, Florida

  • Research Site

    Doral, Florida

  • Research Site

    Edgewater, Florida

  • Research Site

    Fort Lauderdale, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Homestead, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Kissimmee, Florida

  • Research Site

    Miami, Florida

Showing 40 of 356 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.